MedImmune and Advaxis partner on immuno-oncology combination clinical trial

July 22, 2014 AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into a clinical trial collaboration with Advaxis, Inc., a US-based biotechnology company developing cancer immunotherapies. The Phase I/II immunotherapy study will evaluate the safety and efficacy of MedImmune’s investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with Advaxis’ lead cancer immunotherapy vaccine, ADXS-HPV, …

New Products Push Influenza Vaccine Market Above $3billion

A new report out from Kalorama Information estimates that influenza vaccines sales rose by 13% to $3.1 billion in 2013. This figure brings the influenza vaccines market up from $2.8 billion in 2012, and back to the sort of levels we saw before the government’s stockpiling 2010 -as a result of this stockpiling, and perhaps over purchasing, the market dropped …

MD Anderson, MedImmune Join Forces to Advance Cancer Immunotherapy

March 13, 2014 The University of Texas MD Anderson Cancer Center and MedImmune, the global biologics research and development arm of AstraZeneca, will collaborate through MD Anderson’s Moon Shots Program to develop therapies that unleash patients’ immune systems to attack their cancers. “Our collaboration with MedImmune, a leader in the field of immunotherapy, will draw on the strengths of both institutions to …

Sanofi and MedImmune begin shipping quadrivalent flu vaccines

Quadrivalent influenza vaccines are on the way. MedImmune and Sanofi Pasteur have announced they have begun shipment of their respective quadrivalent vaccines for the 2013-2014 season following release by the FDA for US distribution. The 2013-2014 influenza season will be the first season to embrace quadrivalent vaccines. MedImmune's intra-nasal FluMist Quadrivalent, Sanofi's Fluzone Quadrivalent and Glaxo's Fluarix Quadrivalent each contain …

#Vaccine production: #Baxter explore avian #cell-lines, but could algae hold the answer…?

In every industry their is always the endless search to find ‘the-next-BIG-thing', and cell culture vaccine production is no different!  Cell lines from African green monkey to carrots, and Chinese hamster ovary to tobacco have been investigated with varying degrees of success. Now, Baxter have published results on a novel avian cell line, while at the University of Arizona, Dr …

Can #bio-informatic analysis deliver #vaccine #cell line qualification?

One of the biggest challenges standing in the way of cell culture vaccine production is achieving cell line qualification, and standing in the way of this is proving you have scanned for all known and unknown pathogens throughout bio-production. In April the leading players working to try to achieve this goal are going to be in Washington D.C. discussing their …